Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients

Annals of Oncology

Volumn 21, Issue 11, 2010, Pages 2175-2182

  Lim, Y W ^a   Goh, B C ^a,b   Wang, L Z ^a   Tan, S H ^a   Chuah, B Y S ^a   Lim, S E ^a   Iau, P ^a   Buhari, S A ^a   Chan, C W ^a   Sukri, N B ^a   Cordero, M T ^a   Soo, R ^a   Lee, S C ^a,b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Breast cancer; CYP3A4 inhibition; Docetaxel; Ketoconazole; Pharmacokinetics

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DOCETAXEL; DOXORUBICIN; KETOCONAZOLE; ORPHAN NUCLEAR RECEPTOR;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CHINESE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; ETHNIC DIFFERENCE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENOTYPE; HUMAN; INDIAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; NEUTROPHIL; PARTIAL MASTECTOMY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 77958504819     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq230     Document Type: Article

References (28)

1. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35: 361-390.
2. Maurice M, Pichard L, Daujat M et al. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 1992; 6: 752-758.
3. Tang W, Stearns RA. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab 2001; 2: 185-198.
4. First MR, Schroeder TJ, Weiskittel P et al. Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients. Lancet 1989; 2: 1198-1201.
5. First MR, Schroeder TJ, Alexander JW et al. Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. Transplantation 1991; 51: 365-370.
6. Butman SM, Wild JC, Nolan PE et al. Prospective study of the safety and financial benefit of ketoconazole as adjunctive therapy to cyclosporine after heart transplantation. J Heart Lung Transplant 1991; 10: 351-358.
7. Trudeau ME. Docetaxel: a review of its pharmacology and clinical activity. Can J Oncol 1996; 6: 443-457.
8. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999; 36: 99-114.
9. Bruno R, Hille D, Riva A et al. Population pharmacokinetics/pharmacodynamics of docetaxelinphase
10. Bruno R, Vivier N, Veyrat-Follet C et al. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs 2001; 19: 163-169.
11. Goh BC, Lee SC, Wang LZ et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20: 3683-3690.
12. Van Veldhuizen PJ, Reed G, Aggarwal A et al. Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study. Cancer 2003; 98: 1855-1862.
13. Engels FK, Mathot RA, Loos WJ et al. Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. Cancer Biol Ther 2006; 5: 833-839.
14. Engels FK, Loos WJ, Mathot RA et al. Influence of ketoconazole on the fecal and urinary disposition of docetaxel. Cancer Chemother Pharmacol 2007; 60: 569-579.
15. Yong WP, Wang LZ, Tham LS et al. A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. Cancer Chemother Pharmacol 2008; 62: 243-251.
16. Hor SY, Lee SC, Wong CI et al. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. Pharmacogenomics J 2008; 8: 139-146.
17. James K, Eisenhauer E, Christian M et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999; 91: 523-528.
18. Guitton J, Cohen S, Tranchand B et al. Quantification of docetaxel and its main metabolites in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005; 19: 2419-2426.
19. Sparano JA, Wang M, Martino S et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663-1671.
20. Perng RP, Shih JF, Chen YM et al. A phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer. Jpn J Clin Oncol 2000; 30: 429-434.
21. Bang YJ, Kang WK, Kang YK et al. Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 2002; 32: 248-254.
22. Maruyama R, Nishiwaki Y, Tamura T et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008; 26: 4244-4252.
23. Ando M, Watanabe T, Nagata K et al. Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance. J Clin Oncol 2001; 19: 336-342.
24. Harris AL, Cantwell BM, Dowsett M. High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer. Br J Cancer 1988; 58: 493-496.
25. Green VJ, Kokkotou E, Ladias JA. Critical structural elements and multitarget protein interactions of the transcriptional activator AF-1 of hepatocyte nuclear factor 4. J Biol Chem 1998; 273: 29950-29957.
26. Trudeau ME, Eisenhauer EA, Higgins BP et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996; 14: 422-428.
27. Gradishar WJ, Wedam SB, Jahanzeb M et al. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol 2005; 16: 1297-1304.
28. Amat S, Bougnoux P, Penault-Llorca F et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 2003; 88: 1339-1345.